Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 8, 2010, Pages 1076-1083

  Pasquini, Marcelo C ^a   Griffith, Linda M ^b   Arnold, Douglas L ^c   Atkins, Harold L ^d   Bowen, James D ^e   Chen, Jacqueline T ^c,f   Freedman, Mark S ^d   Kraft, George H ^g   Mancardi, Gian Luigi ^h   Martin, Roland ⁱ   Muraro, Paolo A ^j   Nash, Richard A ^k   Racke, Michael K ^l   Storek, Jan ^m   Saccardi, Riccardo ⁿ  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e SWEDISH MEDICAL CENTER   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j Science and Technology   (United Kingdom)

^k Fred Hutchinson Cancer Research Center   (United States)

^l OHIO STATE UNIVERSITY   (United States)

^m UNIVERSITY OF CALGARY   (Canada)

ⁿ UO Ematologia   (Italy)

more..

Author keywords

Allogeneic hematopoietic cell transplantation; Autoimmune disease; Autologous hematopoietic cell transplantation; Clinical trial; Multiple sclerosis

Indexed keywords

ALTERNATIVE MEDICINE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL; DATA BASE; FEASIBILITY STUDY; FOLLOW UP; HUMAN; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; REVIEW; STUDY DESIGN;

CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE SCLEROSIS; REGISTRIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 77954315037     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.03.012     Document Type: Review

References (40)

1. Sospedra M., Martin R. Immunology of multiple sclerosis. Ann Rev Immunol 2005, 23:683-747.
2. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 2006, 354:942-955.
3. Muraro P.A., Douek D.C., Packer A., et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005, 201:805-816.
4. Mancardi G., Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008, 7:626-636.
5. Saccardi R., Di Gioia M., Bosi A. Haematopoietic stem cell transplantation for autoimmune disorders. Curr Opin Hematol 2008, 15:594-600.
6. Schippling S., Heesen C., Zander A., Martin R. Stem cell transplantation in multiple sclerosis. J Neurol 2008, 255(Suppl 6):43-47.
7. Fassas A., Anagnostopoulos A., Kazis A., et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997, 20:631-638.
8. Saccardi R., Kozak T., Bocelli-Tyndall C., et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation Autoimmune Diseases Working Party database. Mult Scler 2006, 12:814-823.
9. Farge D., Labopin M., Tyndall A., et al. Autologous hematopoietic stem cell transplantation (HSCT) for autoimmune diseases: an observational study on 12 years of experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases. Haematologica 2010, 95:284-292.
10. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
11. Saccardi R., Mancardi G.L., Solari A., et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005, 105:2601-2607.
12. Capello E., Saccardi R., Murialdo A., et al. Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Neurol Sci 2005, 26:S200-S203.
13. Burt R.K., Loh Y., Cohen B., et al. Autologous non-myeloablative haematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009, 8:244-253.
14. Stangel M. Hematopoietic stem cell transplantation: hope and hype. Nature Rev Neurol 2009, 5:300-302.
15. Daikeler T., Hugle T., Farge D., et al. Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant 2009, 44:27-33.
16. Griffith L.M., Pavletic S.Z., Tyndall A., et al. Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-sponsored international workshop, Bethesda, MD, March 12-13, 2005. Biol Blood Marrow Transplant 2005, 11:862-870.
17. Lu J.-Q., Storek J., Metz L., et al. Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. Arch Neurol 2009, 66:116-120.
18. Sullivan K.M., Siebold J.R., Mineishi S., et al. Denials of treatment coverage by health insurance carriers restrict patient recruitment on a randomized clinical trial: experience of 95 patients with systemic sclerosis (SSc) enrolled in the SCOT (Scleroderma: Cyclophosphamide or Transplantation) trial. Biol Blood Marrow Transplant 2010, 16(Suppl 1):S164. [Abstract].
19. Weinshenker B.G., Bass B., Rice G.P.A., et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989, 112:133-146.
20. Ebers G.C., Heigenhauser L., Daumer M., et al. Disability as an outcome in MS clinical trials. Neurology 2008, 71:624-631.
21. Cutter G.R., Baier M.L., Rudick R.A., et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999, 122:871-882.
22. Cohen J.A., Cutter J.R., Fischer J.S., et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001, 58:961-967.
23. Petzold A., Eikelenboom M.J., Keir G., et al. The new global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers. Mult Scler 2006, 12:325-328.
24. Liu C., Po A.L.W., Blumhardt L.D. " Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1998, 64:726-729.
25. Hobart J., Lamping D., Fitzpatrick R., et al. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001, 124:962-973.
26. Bar-Zohar D., Agosta F., Goldstaub D., et al. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives. Mult Scler 2008, 14:719-727.
27. Chen J.T., Collins D.L., Atkins H.L., et al. Canadian MS/BMT Study Group. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 2008, 63:254-262.
28. Sormani M.P., Bonzano L., Roccatagliata L., et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009, 65:268-275.
29. Rudick R.A., Fisher E., Lee J.C., et al. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler 2000, 6:365-372.
30. Bielekova B., Martin R. Development of biomarkers in multiple sclerosis. Brain 2004, 127:1463-1478.
31. Hauser S.L., Waubant E., Arnold D.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
32. CAMMS223 Trial Investigators, Coles A.J., Compston D.A.S., et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359:1786-1801.
33. Bielekova B., Richert N., Howard T., et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004, 101:8705-8708.
34. Rice G.P.A., Filippi M., Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000, 54:1145-1155.
35. Krishnan C., Kaplin A.I., Brodsky R.A., et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008, 65:1044-1051.
36. Hartung H.P., Gonsette R., Konig N., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360:2018-2025.
37. Providing clinical evidence of effectiveness for human drug and biological products: guidance for industry. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, May 1998. Available from: or Accessed October 2009. http://www.fda.gov/cber/guidelines.htm.
38. Freedman M., Amato M.P., Atkins H., et al. Haematopoietic stem cell transplantation for severe autoimmune diseases. Panel session report: multiple sclerosis. Bone Marrow Transplant 2010, 45(Suppl 1s):S8-S10.
39. Atkins H., Freedman M. Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis. Methods Mol Biol Neural Cell Transplant 2009, 549:231-246.
40. Chen J.T., Collins D.L., Atkins H.L., et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 2006, 66:1935-1937.